We have recently discovered deflamin (patent WO/2018/060528), an oligomeric polypeptide isolated from the edible seeds of white lupin (Lupinus albus), that reduces MMP-2 and MMP-9 activity in CRC cell lines, in a dose-dependent manner and with an IC50 of 10 μg/mL. Here, MMP2 is linked to colorectal carcinoma.